HopeStage
Back to all studies
TerminatedNCT01987960

Brexpiprazole for PTSD

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Los Angeles and 58 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateDecember 2013
Recruitment status
Terminated
Enrollment listed in the registry
417
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Estonia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01987960
Official title
Show the full official title

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

Recruitment & locations

Terminated

Los Angeles, United States · Riverside, United States · San Diego, United States

48 more locations
  • Bradenton, United States
  • Gainesville, United States
  • Jacksonville, United States
  • North Miami, United States
  • Tampa, United States
  • Indianapolis, United States
  • Roslindale, United States
  • Las Vegas, United States
  • Nashua, United States
  • The Bronx, United States
  • Cincinnati, United States
  • Dayton, United States
  • Portland, United States
  • Norristown, United States
  • Memphis, United States
  • Austin, United States
  • Seattle, United States
  • Tallinn, Estonia
  • Helsinki, Finland
  • Kuopio, Finland
  • Oulu, Finland
  • Tampere, Finland
  • Turku, Finland
  • Fort de France, France
  • Laxou, France
  • Nîmes, France
  • Thuir, France
  • Tours, France
  • Andria, Italy
  • Catania, Italy
  • Lecce, Italy
  • Pisa, Italy
  • Siena, Italy
  • Bialystok, Poland
  • Gdansk, Poland
  • Leszno, Poland
  • Lublin, Poland
  • Belgrade, Serbia
  • Niš, Serbia
  • Novi Kneževac, Serbia
  • Bloemfontein, South Africa
  • Cape Town, South Africa
  • Durban, South Africa
  • Port Elizabeth, South Africa
  • Pretoria, South Africa
  • Falun, Sweden
  • Stockholm, Sweden
  • Uppsala, Sweden

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Does this study involve medication?

Yes. The study involves medication, including Placebo and Brexpiprazole.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies